logo crossbeta

NOVEL APPROACHES FOR TREATING AGE-RELATED DISEASES

Crossbeta Biosciences is a biotech company with a focus on Alzheimer’s and Parkinson’s disease. For both indications we have developed novel immunotherapy candidates targeting the toxic oligomers implicated in these pathologies.

Our Alzheimer program has been spun out into DegenRx and our Parkinson program is transferred to Syngle Therapeutics. Further information regarding DegenRx and Syngle Therapeutics and their drug development activities can be found on their respective websites.

Crossbeta Biosciences BV
PO Box 13283
3507 LG Utrecht
The Netherlands

g.scheefhals@crossbeta.com